GS030
Retinitis Pigmentosa (RP)
Phase 1/2PIONEER study initiated
Key Facts
Indication
Retinitis Pigmentosa (RP)
Phase
Phase 1/2
Status
PIONEER study initiated
Company
About GenSight Biologics
GenSight Biologics is a Paris-based gene therapy company focused on creating transformative treatments for severe inherited retinal and neurodegenerative diseases. Its mission is to translate advanced science into long-lasting, single-administration cures, with its most advanced candidate, Lumevoq (lenadogene nolparvovec), having completed Phase III trials for LHON. The company's strategy leverages two proprietary technology platforms—Mitochondrial Targeting Sequence (MTS) and an optogenetics system—to address unmet medical needs in ophthalmology and beyond, operating with a lean, experienced team to advance its pipeline.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa (RP) Drugs
| Drug | Company | Phase |
|---|---|---|
| MC16 | MitoChem Therapeutics | Preclinical |